Asia Pacific
Refine Search
Pharmaceutical
Japanese drugmaker Eisai has announced that the amyotrophic lateral sclerosis (ALS) treatment Rozebalamin for Injection (mecobalamin) has been launched in Japan as a treatment for slowing progression of functional impairment in amyotrophic lateral sclerosis. 21 November 2024
Biotechnology
San Diego-based Kura Oncology and Japan’s Kyowa Kirin have entered into a global strategic collaboration to develop and commercialize ziftomenib. 21 November 2024
Pharmaceutical
Shanghai-based Leading Tac Pharmaceutical has announced the successful completion of a series A financing round, raising over 100 million yuan ($14 million). 21 November 2024
Pharmaceutical
Ascentage Pharma will see its investigational BCL-2 selective inhibitor, lisaftoclax, assessed under China’s Priority Review scheme. 20 November 2024
Pharmaceutical
California, USA-based biotech Cytokinetics saw its shares fall as much as 4% to $9.67 yesterday, after it announced a deal with Germany’ Bayer. 20 November 2024
Biotechnology
Californian oncology-focused biotech Avenzo Therapeutics has announced a pair of important updates. 19 November 2024
Pharmaceutical
Big pharmas are not deterred by China’s increasingly complex business environment. Instead, they are changing strategies to minimize risks while continuing to benefit from China, said speakers at ChinaTrials held last week in Shanghai. 18 November 2024
Biosimilars
Following US approval in May this year, South Korea’s Samsung Bioepis and US biotech Biogen have now won approval from the European Commission (EC) for their Opuviz 40mg/mL solution for injection in a vial, a biosimilar referencing Regeneron and Bayer’s Eylea (aflibercept). 18 November 2024
Biotechnology
Shanghai-based Junshi Biosciences has received UK regulatory approval for Loqtorzi (toripalimab) in nasopharyngeal carcinoma (NPC) and esophageal squamous cell carcinoma (ESCC). 18 November 2024
Biotechnology
Chinese biotech Keymed Biosciences has entered an exclusive licensing agreement with Platina Medicines for its bispecific antibody candidate, CM336. 18 November 2024
Pharmaceutical
In yet another sign of the mounting interest in radiopharmaceuticals, Tongrui Biopharma, a Chinese innovator in this area, has announced the completion of a $100 million series A+ financing round. 18 November 2024
Biotechnology
Shanghai-based biopharma Zai Lab has announced the pricing of its underwritten public offering at $25.50 per share, aiming to raise around $200 million. 15 November 2024
Biosimilars
South Korean biosimilars company Celltrion today announced its acquisition of iQone Healthcare Switzerland a specialty pharmaceutical company focused on distribution, sales, and marketing in Switzerland. 15 November 2024
Biotechnology
Merck & Co has entered into an exclusive global license to develop, manufacture and commercialize LM-299 from China-based clinical-stage biotech LaNova Medicines, bringing the US pharma giant into the newly attractive PD-1/VEGF bispecific antibody space. 15 November 2024
Biotechnology
Japanese drugmaker Nippon Shinyaku and USA-based Atsena Therapeutics have entered into an exclusive license agreement for the commercialization of ATSN-101 in the USA and Japan for advancing Atsena’s first- in-class, investigational gene therapy ATSN-101 for Leber congenital amaurosis caused by biallelic mutations in GUCY2D (LCA1). 13 November 2024
Biotechnology
Anglo-American biotech Apollo Therapeutics and China-based Sunshine Lake Pharma have signed an exclusive license agreement to develop APL-18881, a bi-specific fusion protein aimed at treating metabolic diseases. 13 November 2024
Biotechnology
Dutch firm Argenx and China’s Zai Lab have received an approval from the National Medical Products Administration (NMPA) for Vyvgart Hytrulo (efgartigimod alfa). 13 November 2024
Biotechnology
Although it is seeing a downturn in sales and profits, German biotech BioNTech is continuing to acquire assets with the cash pile it made through the covid pandemic, notably iis Comirnaty vaccine that was developed with Pfizer (NYSE: PFE). 13 November 2024
Biotechnology
Sino-American oncology company BeiGene has announced third-quarter 2024 financials, showing the total revenues was $1,002 million, up 28% compared to $781 million in the same period of 2023. 13 November 2024
Pharmaceutical
Li Li, Commissioner of China's National Medical Products Administration (NMPA), and Mette Aaboe Hansen, interim director general of Danish Medicines Agency, have signed a letter of intent to promote bilateral cooperation in regulation of drugs and medical devices. 11 November 2024
Pharmaceutical
The Chinese National Medical Products Administration (NMPA) held a meeting recently to carry out the 2023 annual review of the vaccine regulatory quality management system (QMS). 10 June 2024
Pharmaceutical
Japanese drugmaker Shionogi has entered into an option agreement with French firm Cilcare to acquire the exclusive license for the development, manufacturing, and commercialization of CIL001 and/or CIL003, a hearing loss treatment drug candidates worldwide. 8 June 2024
Pharmaceutical
Singaporean speciality pharma company Hyphens Pharma International has entered into an exclusive license, development and commercialization agreement with Japanese drugmaker Maruho. 6 June 2024
Biotechnology
USA-based ArriVent BioPharma has entered into a collaboration agreement with a unit of Chinese biotech Alphamab Oncology, to discover, develop and commercialize novel antibody-drug conjugates (ADCs) for the treatment of cancers. 6 June 2024
Biotechnology
Brandon Capital, Australasia’s leading life sciences venture capital firm, has announced the launch of its sixth fund. 5 June 2024
Pharmaceutical
Japanese pharma major Shionogi says it is responding to the urgent global need for additional antimicrobial research and development by establishing its first discovery laboratory in San Diego, California, USA. 4 June 2024
Biotechnology
Japanese drugmaker Eisai today said it will strengthen and continue its venture investment business. 3 June 2024
Biotechnology
Japan’s Nxera Pharma has expanded its strategic R&D partnership with UK-based computational biology company PrecisionLife into autoimmune disorders with the potential to identify new drug targets for the treatment of complex, chronic conditions. 30 May 2024
Pharmaceutical
Globally, the devastating and widespread impact of neurological disorders like Alzheimer's disease, epilepsy, Parkinson’s disease and depression is only getting worse. 30 May 2024
Biosimilars
Bio-Thera Solutions has partnered with STADA Arzneimittel for the commercialization of BAT2506, a biosimilar candidate to Simponi (golimumab). 30 May 2024
Biotechnology
Shares of Swedish biotech Calliditas Therapeutics shot up more than 78% to 202.60 kronor by late afternoon, on news of a takeover bid from Asahi Kasei. 28 May 2024
Biotechnology
Privately-held Swiss drug firm Ewopharma it has entered into a strategic commercial collaboration with China’s CStone Pharmaceuticals to gain rights for sugemalimab in Switzerland and 18 Central Eastern European countries (CEE). 28 May 2024
Pharmaceutical
USA-based Nippon Shinyaku subsidiary NS Pharma has published a disappointing initial analysis from an important trial of Viltepso (viltolarsen). 28 May 2024
Pharmaceutical
With its potential to revolutionize type 2 diabetes (T2D) treatment, Chinese firm Innovent Biologics’ (HKG: 1801) mazdutide's success could reshape the landscape of diabetes therapeutics in China. 25 May 2024
Generics
Indian biotech major Biocon has signed an exclusive licensing and supply agreement with South Korea’s Handok, for the commercialization of its vertically integrated, complex drug product, synthetic liraglutide. 24 May 2024
Biosimilars
The European Commission (EC) has approved Omlyclo (CT-P39), an omalizumab biosimilar referencing Xolair. 24 May 2024
Pharmaceutical
The European Commission (EC) has approved the label update of both Nilemdo (bempedoic acid) and Nustendi (bempedoic acid / ezetimibe fixed-dose combination (FDC)), as treatments for hypercholesterolaemia (high levels of cholesterol) and to reduce the risk of adverse cardiovascular events. 24 May 2024
Biotechnology
Privately-held Chinese developer of molecular glue degraders for cancer treatment Degron Therapeutics has entered into a collaboration and exclusive license agreement with Japan’s largest drugmaker Takeda Pharma. 23 May 2024
Biotechnology
Roche’s Japan-based majority-owned company Chugai has launched PiaSky for injection 340 mg (crovalimab), a pH-dependent binding humanized anti-complement (C5) monoclonal antibody for the treatment of paroxysmal nocturnal hemoglobinuria (PNH), in the Asian country. 23 May 2024
Pharmaceutical
Japanese drugmaker Daiichi Sankyo has established two research institutes: DS Research Institute Boston and DS Research Institute Munich, in Cambridge, Massachusetts, USA and Munich, Germany, respectively. 23 May 2024
Sign up to receive email updates
Join industry leaders for a daily roundup of biotech & pharma news
Today's issue
Company Spotlight
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze